Insulin resistance, defined as the inability of insulin to exert a normal biological action at the
level of its target tissues, is one of the principal patho-genetic defects of type 2 diabetes …

Metformin is now established as a first-line antidiabetic therapy for the management of type
2 diabetes. Its early use in treatment algorithms is supported by lack of weight gain, low risk …

Metformin is a biguanide that has been used worldwide for the treatment of type 2 diabetes
for the past 4 decades. It improves glycemic control by enhancing insulin sensitivity in liver …

Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose
concentrations in type 2 (non-insulin-dependent) diabetes without causing overt …

Aims/hypothesis As adding metformin to insulin therapy has been advocated in type 1
diabetes, we conducted a systematic review of published clinical trials and clinical trial …

Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes
mellitus for nearly 8 years. Over this period of time, it has become the most widely prescribed …

Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose
requirement. Guidelines recommend that it can improve glucose control in those who are …

Metformin is one of the most popular oral glucose-lowering medications, widely considered
to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there …

Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2
(noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial …